Northwest Biotherapeutics (NWBO) Income towards Parent Company: 2010-2024
Historic Income towards Parent Company for Northwest Biotherapeutics (NWBO) over the last 15 years, with Dec 2024 value amounting to -$74.3 million.
- Northwest Biotherapeutics' Income towards Parent Company fell 0.36% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$73.4 million, marking a year-over-year decrease of 5.42%. This contributed to the annual value of -$74.3 million for FY2024, which is 22.27% down from last year.
- Per Northwest Biotherapeutics' latest filing, its Income towards Parent Company stood at -$74.3 million for FY2024, which was down 22.27% from -$60.7 million recorded in FY2023.
- In the past 5 years, Northwest Biotherapeutics' Income towards Parent Company registered a high of -$57.7 million during FY2021, and its lowest value of -$95.1 million during FY2020.
- In the last 3 years, Northwest Biotherapeutics' Income towards Parent Company had a median value of -$73.2 million in 2022 and averaged -$69.4 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first slumped by 207.39% in 2020, then surged by 39.34% in 2021.
- Over the past 5 years, Northwest Biotherapeutics' Income towards Parent Company (Yearly) stood at -$95.1 million in 2020, then skyrocketed by 39.34% to -$57.7 million in 2021, then decreased by 26.92% to -$73.2 million in 2022, then rose by 17.07% to -$60.7 million in 2023, then decreased by 22.27% to -$74.3 million in 2024.